{"organizations": [], "uuid": "57faae814f0b9b5b2546e338b7f1039750f7b036", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-eagle-pharmaceuticals-vasopressin/brief-eagle-pharmaceuticals-vasopressin-anda-accepted-for-filing-by-the-fda-idUSASC09VW6", "country": "US", "domain_rank": 408, "title": "BRIEF-Eagle Pharmaceuticals’ Vasopressin ANDA Accepted For Filing By The FDA", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-16T14:10:00.000+03:00", "replies_count": 0, "uuid": "57faae814f0b9b5b2546e338b7f1039750f7b036"}, "author": "", "url": "https://www.reuters.com/article/brief-eagle-pharmaceuticals-vasopressin/brief-eagle-pharmaceuticals-vasopressin-anda-accepted-for-filing-by-the-fda-idUSASC09VW6", "ord_in_thread": 0, "title": "BRIEF-Eagle Pharmaceuticals’ Vasopressin ANDA Accepted For Filing By The FDA", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-eagle pharmaceuticals", "sentiment": "negative"}, {"name": "fda", "sentiment": "negative"}, {"name": "fda reuters staff    eagle pharmaceuticals inc", "sentiment": "none"}, {"name": "endo international plc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 16 (Reuters) - Eagle Pharmaceuticals Inc:\n* EAGLE PHARMACEUTICALS’ VASOPRESSIN ANDA ACCEPTED FOR FILING BY THE FDA\n* EAGLE PHARMACEUTICALS INC - PRODUCT IS GENERIC VERSION OF ENDO INTERNATIONAL PLC’S ORIGINAL VASOSTRICT FORMULATION Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": [], "published": "2018-04-16T14:10:00.000+03:00", "crawled": "2018-04-16T14:28:09.000+03:00", "highlightTitle": ""}